SEC Form 4 research
| Issuer | Inhibrx Biosciences, Inc. |
|---|---|
| Tickers | INXB, INBX |
| Reporting owners | 17 |
| Officers and directors | 5 |
| Last public filing | 2026-10-14 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-14 | 2026-10-14 | Lappe Mark | P | 100 | $85.76 | Not reported |
| 2026-10-14 | 2026-10-14 | Lappe Mark | P | 2,451 | $85 | Not reported |
| 2026-10-14 | 2026-10-14 | Lappe Mark | P | 2,449 | $84.07 | Not reported |
| 2026-10-14 | 2026-10-14 | Lappe Mark | P | 100 | $85.76 | Not reported |
| 2026-10-14 | 2026-10-14 | Lappe Mark | P | 2,470 | $85 | Not reported |
| 2026-10-14 | 2026-10-14 | Lappe Mark | P | 2,470 | $84.07 | Not reported |
| 2026-09-28 | 2026-09-28 | Lappe Mark | P | 3,000 | $101.7 | Not reported |
| 2026-09-28 | 2026-09-28 | Lappe Mark | P | 1,500 | $98.88 | Not reported |
| 2026-09-28 | 2026-09-25 | Lappe Mark | P | 2,176 | $99.6 | Not reported |
| 2026-09-28 | 2026-09-25 | Lappe Mark | P | 3,324 | $98.87 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.